[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current interventions as of 25/11/2020: Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit; a doctor will explain the study and answer any questions they may have. If the volunteer decides to take part; they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history and performing a physical examination if deemed necessary; taking blood tests for SARS-CoV-2 antibodies; urinary pregnancy test for women; and measuring blood pressure and temperature. Participants will be randomised (1:1 using block randomisation) to receive either ChAdOx1 nCoV-19 or MenACWY (licensed control vaccine). Participants will also be advised to take paracetamol for 24 hours after vaccination if there are no contraindications to doing so. Participants will be given two doses of ChAdOx1 nCoV-19 or MenACWY; 4-12 weeks apart. ChAdOx1 nCoV-19: 5 x 10(10) vp Men ACWY: 0.5 ml Two doses of ChAdOx1 nCoV-19 or MenACWY given intramuscularly. Paracetamol 1 g taken 6 hourly for the first 24 hours after receiving vaccine. Total follow up time 1 year for each study arm. All participants will be invited to follow-up visits at day 28; 90; 182 and 364 after their last vaccination. Participants will be asked to contact the study team if they develop symptoms suggestive of COVID-19 at any point during the trial. Symptomatic participants will be asked to present for a visit to test for SARS-CoV-2 PCR. Prev", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "1", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1", "treatment_id": 780, "treatment_name": "Menacwy vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit; a doctor will explain the study and answer any questions they may have. If the volunteer decides to take part; they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history and performing a physical examination if deemed necessary; taking blood tests for SARS-CoV-2 antibodies; urinary pregnancy test for women; and measuring blood pressure and temperature. Participants will be randomised (1:1 using block randomisation) to receive either ChAdOx1 nCoV-19 or MenACWY (licensed control vaccine). Participants will also be advised to take paracetamol for 24 hours after vaccination if there are no contraindications to doing so. ChAdOx1 nCoV-19: 5 x 10(10) vp Men ACWY: 0.5 ml One dose of ChAdOx1 nCoV-19 or MenACWY given intramuscularly. Single intervention only. Paracetamol 1 gm taken 6 hourly for the first 24 hours after receiving vaccine. Total follow up time 1 year for each study arm. All participants will be invited to follow-up visits at day 28; 90; 182 and 364 and participants will be asked to contact the study team if they develop symptoms suggestive of COVID-19 at any point during the trial. Symptomatic participants will be asked to present for a visit to test for SARS-CoV-2 PCR.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]